The phase II BYLieve trial confirmed that adding alpelisib to ET is effective for relapsed HR+/HER2− breast cancer subjects carrying a PIK3CA mutation and progressing on CDK4/6is and ET [131]. Here, PIK3CA is linked to breast cancer.